Inherited thrombophilia: Memorandum from a joint WHO/international society on Thrombosis and Haemostasis meeting

Bulletin of the World Health Organization

Volumn 75, Issue 3, 1997, Pages 177-189

  Boulyjenkov, V ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ENVIRONMENTAL FACTOR; HEREDITY; HUMAN; PATHOGENESIS; REVIEW; THROMBOPHILIA; WORLD HEALTH ORGANIZATION;

ANTITHROMBIN III DEFICIENCY; BLOOD COAGULATION; HUMANS; PREVALENCE; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; THROMBOSIS;

EID: 0030770616     PISSN: 00429686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Allaart CF, Briet E. Familial venous thrombophilia. In: Bloom AL et al., eds. Haemostasis and thrombosis. Edinburgh, Churchill Livingstone, 1994: 1349-1360.
2. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90: 1004-1008.
3. Bertina RM et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature, 1994, 369: 64-67.
4. Rosendaal FR et al. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood, 1995, 85: 1504-1508.
5. Voorberg J et al. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet, 1994, 343: 1535-1536.
6. Lane DA et al. Pleiotropic effects of antithrombin strand 1C substitution mutations. Journal of clinical investigation, 1992, 90: 2422-2433.
7. Lane DA et al. Antithrombin III mutation database: first update. Thrombosis and haemostasis, 1993, 70: 361-369.
8. Finazzi G, Caccia R, Barbui T. Different prevalence of thromboembolism in the subtypes of congenital antithrombin III deficiency: review of 404 cases. Thrombosis and haemostasis, 1987, 58: 1094.
9. Olds RJ et al. (ATT) trinucleotide repeats in the antithrombin gene and their use in determining the origin of repeated mutations. Human mutation, 1994, 4: 31-41.
10. Reitsma PH et al. Protein C deficiency: a database of mutations, 1995 update. Thrombosis and haemostasis, 1995, 73: 876-889.
11. Aiach M, Gandrille S, Emmerich J. A review of mutations causing deficiencies of antithrombin, protein C and protein S. Thrombosis and haemostasis, 1995, 74: 81-89.
12. Borgel D et al. Molecular defects responsible for type I and IIa protein S (PS) deficiencies in a panel of 120 French families. Thrombosis and haemostasis, 1995, 73: 1256.
13. Reitsma PH, Ploos van Amstel HK, Bertina RM. Three novel mutations in five unrelated subjects with hereditary protein S deficiency type I. Journal of clinical investigation, 1994, 93: 486-492.
14. Gomez E et al. Identification of eight point mutations in protein S deficiency type I - analysis of 15 pedigrees. Thrombosis and haemostasis, 1995, 73: 750-755.
15. Gandrille S et al. Identification of 15 different candidate causal point mutations and three polymorphisms in 19 patients with protein S deficiency using a scanning method for the analysis of the protein S active gene. Blood, 1995, 85: 130-138.
16. Hayashi T et al. Protein S Tokushima: abnormal molecule with a substitution of Glu for Lys-155 in the second epidermal growth factor-like domain of protein S. Blood, 1994, 83: 683-690.
17. Shen L, Dahlback B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor Villa. Journal of biological chemistry, 1994, 269: 18735-18738.
18. Jenny RJ, Tracy PB, Mann KG. The physiology and biochemistry of factor V. In: Bloom AL et al., eds. Haemostasis and thrombosis. Edinburgh, Churchill Livingstone, 1994: 465-476.
19. Greengard JS et al. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet, 1994, 343: 1361-1362.
20. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet, 1995, 346: 1133-1334.
21. Ohlin AK, Marlar RA. The first mutation identified in the thrombomodulin gene in a 45-year-old man presenting with thromboembolic disease. Blood, 1995, 85: 330-336.
22. Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen. Thrombosis and haemostasis, 1995, 73: 151-161.
23. Falcon CR et al. High prevalence of hyperhomocysteinemia in patients with juvenile venous thrombosis. Arteriosclerosis and thrombosis, 1994, 14: 1080-1083.
24. Dahlback B, Stenflo J. A natural anticoagulant pathway: protein C, S, C4b-binding protein and thrombomodulin. In: Bloom AL et al., eds. Haemostasis and thrombosis. Edinburgh, Churchill Livingstone, 1994: 671-698.
25. Dolan G, Preston FE. Familial plasminogen deficiency and thromboembolism. Fibrinolysis, 1988, 2 (suppl. 2): 26-34.
26. Gladson CL et al. The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous throm-bosis. Thrombosis and haemostasis, 1988, 59: 18-22.
27. Tait RC et al. Plasminogen levels and putative prevalence of deficiency in 4500 blood donors. British journal of haematology, 1991, 77 (suppl. 1): 10.
28. Lijnen HR, Hoylaerts M, Collen D. Isolation and characterization of a human plasma protein with affinity for the lysine binding sites in plasminogen. Role in the regulation of fibrinolysis and identification as histidine rich glycoprotein. Journal of biological chemistry, 1980, 255: 10214-10222.
29. Engesser L et al. Familial elevation of plasma histidine-rich glycoprotein in a family with thrombophilia. British journal of haematology, 1987, 67: 355-358.
30. Castaman G et al. High levels of histidine-rich glycoprotein and thrombotic diathesis. Report of two unrelated families. Thrombosis research, 1993, 69: 279-305.
31. Koster T et al. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep vein thrombosis. Lancet, 1995, 345: 152-155.
32. Griffin JH et al. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood, 1993, 82: 1989-1993.
33. Tait RC et al. Prevalence of antithrombin III deficiency subtypes in 4000 healthy blood donors. Thrombosis and haemostasis, 1991, 65: 839.
34. Tait RC et al. Prevalence of protein C deficiency in the healthy population. Thrombosis and haemostasis, 1995, 73: 87-93.
35. Miletich J, Sherman L, Broze G, Jr. Absence of thrombosis in subjects with heterozygous protein C deficiency. New England journal of medicine, 1987, 317: 991-996.
36. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. New England journal of medicine, 1994, 330: 517-522.
37. Ridker PM et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction. New England journal of medicine, 1995, 332: 912-917.
38. Koster T et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet, 1993, 342: 1503-1506.
39. Finazzi G, Barbui T. Different incidence of venous thrombosis in patients with inherited deficiencies of antithrombin III, protein C and protein S. Thrombosis and haemostasis, 1994, 71: 15-18.
40. De Stefano V et al. Clinical manifestations and management of inherited thrombophilia: retrospective analysis and follow-up after diagnosis of 238 patients with congenital deficiency of antithrombin III, protein C, protein S. Thrombosis and haemostasis, 1994, 72: 352-358.
41. Briet E, Broekmans AW. Hereditary protein S deficiency. In: Bertina RM, ed. Protein C and related proteins. Edinburgh, Churchill Livingstone, 1988: 203-212.
42. Broekmans AW, Conard J. Hereditary protein C deficiency. In: Bertina RM, ed. Protein C and related proteins. Edinburgh, Churchill Livingstone, 1988: 160-202.
43. Demers C et al. Thrombosis in antithrombin-III-deficient persons. Report of a large kindred and literature review. Annals of internal medicine, 1992, 116: 754-761.
44. Zoller B et al. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. Journal of clinical investigation, 1994, 94: 2521-2524.
45. De Stefano V et al. Thrombosis during pregnancy and surgery in patients with congenital deficiency of antithrombin III, protein C, protein S. Thrombosis and haemostasis, 1994, 71: 799-800.
46. De Stefano V et al. Thrombotic risk during pregnancy and puerperium in women with APC-resistance. Effective subcutaneous heparin in prophylaxis in a pregnant patient. Thrombosis and haemostasis, 1995, 74: 793-794.
47. Chowdhury V et al. Homozygous antithrombin deficiency: report of two new cases (99Leuto Phe) associated with arterial and venous thrombosis. Thrombosis and haemostasis, 1994, 72: 198-202.
48. Hakten et al. Two cases of homozygous antithrombin III deficiency in a family with congenital deficiency of ATIII. In: Senzinger H, Vinazzer H, eds. Thrombosis and haemorrhagic disorders. Schmitt & Meyer GmbH, Würzburg, 1989: 177-181.
49. Tripodi A et al. Asymptomatic homozygous protein C deficiency. Acta haematologica, 1990, 83: 152-155.
50. Mahasandana C et al. Neonatal purpura fulminans associated with homozygous protein S deficiency. Lancet, 1990, 335: 61-62.
51. Cruickshank MK et al. A standard heparin monogram for the management of heparin therapy. Archives of internal medicine, 1991, 151: 333-337.
52. Raschke RA et al. The weight-based heparin dosing nomogram compared with a standard care nomogram. Annals of internal medicine, 1993, 199: 874-881.
53. Schwartz RS et al. Clinical experiences with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin. American journal of medicine, 1989, 87: 53S-60S.
54. Schulman S et al. A comparison of six weeks with six months of oral anticoagulation after a first episode of venous thromboembolism. New England journal of medicine, 1995, 332: 1661-1665.
55. Levine MN, Hirsh J, Gent M. Optimal duration of oral anticoagulant therapy: a randomised trial comparing four weeks with three months of warfarin in patients with proximal deep venous thrombosis. Thrombosis and haemostasis, 1995, 74: 606-611.
56. Devor M et al. Estrogen replacement therapy and the risk of venous thrombosis. American journal of medicine, 1992, 92: 275-285.
57. Conard J et al. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: study of 78 women. Thrombosis and haemostasis, 1990, 63: 319-320.
58. Ginsberg JS, Hirsh J. Anticoagulants during pregnancy. Annual review of medicine, 1989, 40: 79-86.
59. Broekmans AW et al. Protein C (PC) and coumarin-induced skin necrosis. Thrombosis research, 1986, 6: 137.
60. Friedman KD et al. Warfarin-induced skin necrosis in a patient with protein S deficiency. Blood, 1986, 68 (suppl): 333a.
61. Schramm W et al. Treatment of coumarin-induced skin necrosis with a monoclonal antibody purified protein C concentrate. Archives of dermatology, 1993, 129: 753-756.
62. Yuen P et al. Purpura fulminans in a Chinese boy with congenital protein C deficiency. Pediatrics, 1986, 77: 670-677.
63. Vigano et al. Decrease in protein C antigen and formation of an abnormal protein soon after starting oral anticoagulant therapy. British journal of haematology, 1984, 57: 213-220.
64. Heijboer H et al. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. New England journal of medicine, 1990, 323: 1512-1516.
65. Koster T et al. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood, 1995, 85: 2756-2761.
66. Briët E et al. Thrombophilia: its causes and a rough estimate of its prevalence. Thrombosis and haemostasis, 1987, 58: 39.
67. Scharrer I et al. Incidence of defective tPA release in 158 unrelated young patients with venous thrombosis in comparison to PC-, PS-, ATIII-, fibrinogen-, and plasminogen-deficiency. Thrombosis and haemostasis, 1987, 58: 72.
68. Ben Tal O, Zivelin A, Seligsohn U. The relative frequency of hereditary thrombotic disorders among 107 patients with thrombophilia in Israel. Thrombosis and haemostasis, 1989, 61: 50-54.
69. Tabernero MD et al. Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis. American journal of hematology, 1991, 36: 249-254.